Abstract 52P
Background
The majority of colorectal cancers (CRCs), lung carcinomas (LCs) and melanomas contain hot-spot mutations in driver genes. This study evaluated the feasibility of disease monitoring using individual single-mutation tests for the analysis of circulating tumor DNA (ctDNA) in plasma.
Methods
The study included 49 patients with KRAS/BRAF-mutated CRC, EGFR-mutated LC, or BRAF-mutated melanoma, who received systemic treatment for metastatic disease. Blood samples were collected every 25-30 days; the number of time points varied from 2 to 12 for each patient with the individual follow-up ranging from 29 to 523 days (mean 208.7 ± 18.16). A total of 242 plasma samples were analyzed by droplet digital PCR to quantify ctDNA fragments carrying the corresponding driver mutation.
Results
In 25 patients (49%) no circulating mutant copies were detected in any of the serial samples; 24/25 (96%) of these ctDNA-negative subjects experienced either the reduction of tumor lumps or stable disease during the entire observation period. Twenty-four patients showed variations in the ctDNA status during the disease course. In 21/24 (88%) of these patients, the changes in the concentration of mutated ctDNA closely followed the dynamics of tumor volume as observed by computed tomography (CT). There were instances in which tumor progression was detected by liquid biopsy earlier than by imaging tools. One LC patient demonstrated an emergence of EGFR T790M mutation in the blood 126 days prior to tumor progression as registered by CT; in two other cases, the tumor growth was radiologically documented 23 and 34 days after the appearance of mutated ctDNA in plasma.
Conclusions
Serial ddPCR-based assessment of single driver mutations in ctDNA allows efficient monitoring of the efficacy of therapy in diverse categories of cancer patients. This work has been supported by the Russian Science Foundation grant #17-75-30027.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation grant #17-75-30027.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract